Search

Your search keyword '"Goldstein EJ"' showing total 348 results

Search Constraints

Start Over You searched for: Author "Goldstein EJ" Remove constraint Author: "Goldstein EJ"
348 results on '"Goldstein EJ"'

Search Results

1. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2

2. Genomic reconstruction of the SARS-CoV-2 epidemic in England

3. Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)

4. Genomic reconstruction of the SARS-CoV-2 epidemic in England

5. Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

6. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2

7. The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis

8. Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer

9. Spatial growth rate of emerging SARS-CoV-2 lineages in England, September 2020-December 2021

12. Disseminated histoplasmosis in an immunosuppressed patient successfully treated with isavuconazole.

13. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning.

14. Comparative susceptibility of Gemella morbillorum to 13 antimicrobial agents.

15. Bulleidia extructa: An underappreciated anaerobic pathogen.

16. Necrotizing Soft Tissue Infections.

17. Performance characteristics of the SpeeDx PlexPCR VHS assay for the molecular detection of herpes simplex virus, varicella zoster virus, and Treponema pallidum in lesion swabs.

18. Investigating utilising the Alinity m platform to detect hepatitis C virus RNA in dried blood spot samples.

19. Impact of implementing respiratory point-of-care testing in a regional haemato-oncology unit.

20. The Influence of Microaffirmations on Undergraduate Persistence in Science Career Pathways.

21. Yellow fever vaccine-associated neurological disease: it is not just the silver generation at risk.

22. In-house validation of the cobas Liat influenza A/B and RSV assay for use with gargles, sputa and endotracheal secretions.

23. Integrating patient and whole-genome sequencing data to provide insights into the epidemiology of seasonal influenza A(H3N2) viruses.

24. 'Speaking Truth' Protects Underrepresented Minorities' Intellectual Performance and Safety in STEM.

25. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals.

26. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.

27. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.

28. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.

29. Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection.

30. Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines.

31. Ridinilazole: a novel therapy for Clostridium difficile infection.

32. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.

33. Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability.

34. Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.

35. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

36. Reply to Solnick.

37. The times they are a-changin': new antibacterials for skin and skin structure infections.

38. A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+).

39. Lactobacillus species: taxonomic complexity and controversial susceptibilities.

40. Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship.

41. Pathway to Prevention of Nosocomial Clostridium difficile Infection.

42. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.

43. Animals in healthcare facilities: recommendations to minimize potential risks.

44. Clostridium difficile: improving the prevention paradigm in healthcare settings.

45. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.

46. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.

47. Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

48. Bacterial counts from five over-the-counter probiotics: are you getting what you paid for?

49. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence.

50. Therapy of Clostridium difficile infection: perspectives on a changing paradigm.

Catalog

Books, media, physical & digital resources